Drug discovery & regenerative medicine
From thousands of molecules to the few that matter
Dhar Biosciences discovers and develops medicines for diseases that need better treatments. We pair strong disease biology with careful screening and medicinal chemistry, and we advance only the candidates the data supports.
- Hits
- 7
- Hit rate
- 2.2%
- Z′
- 0.81
Approach
Every program earns its next step.
Drug discovery is a long sequence of decisions. We define the evidence a program needs before it moves forward, and we hold to it.
-
Target validation
We start with targets that have strong human evidence linking them to disease, then confirm the biology in cell systems that reflect the patient.
→ Validated target -
Hit finding
We screen broadly and confirm carefully. Every hit is retested in dose response and checked in an orthogonal assay before chemistry begins.
→ Confirmed hit series -
Lead optimization
Medicinal chemists improve potency, selectivity, and drug-like properties together, guided by structure and by measured data on every new analog.
→ Optimized lead -
Candidate selection
A molecule becomes a development candidate when its efficacy, exposure, and safety data make a convincing case for the clinic.
→ Development candidate
Science
Most programs fail late. We work to find out early.
A single-concentration screen finds starting points. A full dose–response curve tells us whether a compound is worth pursuing. We measure the properties that end programs as early as we can, so our effort goes to molecules with a real chance in the clinic.
- Potency
- IC₅₀ and EC₅₀ in biochemical and cellular assays
- Selectivity
- Counter-screens against related targets and a broad safety panel
- Exposure
- ADME and pharmacokinetics from the earliest analogs
- Safety
- In vitro toxicity flags before any in vivo study
Regenerative medicine
Mesenchymal stem cells, measured like medicines.
Mesenchymal stem cells (MSCs) are adult stromal cells found in bone marrow, fat, and umbilical cord tissue. They can calm harmful inflammation and help damaged tissue recover, mostly through the signals they release. Our regenerative medicine program develops MSC therapies with the same standards of evidence we apply to drug discovery.
How MSCs work
- Immune balance
- MSCs damp overactive T-cell and macrophage responses through mediators such as PGE₂, IDO, and TGF-β.
- Tissue repair
- Growth factors and extracellular vesicles released by MSCs can support new blood vessel growth and help injured cells survive.
- Differentiation
- In culture, MSCs can become bone, cartilage, and fat cells. This is one of the defining tests of MSC identity.
Every lot we make is tested for identity, viability, sterility, and potency before it is used in a study.
Tri-lineage potential
Each lot is induced toward bone, fat, and cartilage, then stained to confirm the result. Shown here as illustrations of typical staining.
-
BoneAlizarin Red S · calcium deposits
-
FatOil Red O · lipid droplets
-
CartilageAlcian Blue · proteoglycan matrix
Investigational. Our MSC therapies are in development and have not been approved by the FDA or any other regulator. We do not provide them as treatments outside of authorized clinical studies.
Pipeline
Programs where patients need more options.
Our programs are at different stages of discovery and development. We update this page as they reach new milestones.
Drug discovery 3 programs
-
DB-101
Oncology
Solid tumors
IND-enabling -
DB-204
Immunology
Autoimmune and inflammatory disease
Lead optimization -
DB-312
Neuroscience
Neurodegenerative disease
Discovery
Cell therapy Mesenchymal stem cells · 1 program
-
DBM-101
Musculoskeletal
Knee osteoarthritis
Preclinical
Partnering
Bring us a target, a molecule, or a hard question.
We work with companies, academic groups, and investors who care about rigorous science.
Pharma and biotech
Licensing and co-development for programs from lead optimization onward. We share data early and in full.
Academic labs
Collaborations that turn well-validated biology into drug discovery programs, with clear terms on publication and IP from the start.
Investors
We're glad to walk through our programs, data, and plans in detail with investors who know the field.
Careers
Join the lab.
We're building a team of chemists and biologists who like hard problems and clear data. We hire across discovery, from the first assay to the candidate package.
- Medicinal chemistry
- Assay biology
- Structural biology
- Computational chemistry
- DMPK
- In vivo pharmacology
Send a CV and a short note about work you're proud of to dharbiosciences@gmail.com.